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ABSTRACT
To provide new insights into the in vivo regulation of iodothyronine
deiodinases in the different tissues of the rat, we have evaluated the
effects on these enzymatic activities of T4 or T3 infusions into thy-
roidectomized rats.
Thyroidectomized rats were infused with placebo, T4, or T3. Pla-
cebo-infused intact rats served as euthyroid controls. Plasma and
samples of cerebral cortex, brown adipose tissue, pituitary, liver, and
lung were obtained after 12–13 days of infusion. Plasma TSH, plasma
and tissue T4 and T3, and iodothyronine deiodinase activities were
determined.
Type II 59-deiodinase (DII) was increased in cortex, brown adipose
tissue, and pituitary from animals infused with placebo. DII activity
returned to normal only with T4 infusion, remaining elevated in the
animals infused with T3 alone despite normal tissue T3 concentra-
tions. Cortex type III 5-deiodinase was only increased when hyper-
thyroidism was induced by infusion of T3. Liver type I 59-deiodinase
(DI) paralleled the changes in plasma and tissue T3 regardless of
whether T4 or T3 was infused. On the contrary, the increase in lung
DI, proportional to the increases in plasma and tissue T3, was higher
when T4 was infused. As a rule, the tissues with DII presented a
tighter homeostasis in their T3 concentrations than the tissues with
DI.
In conclusion, the regulation of iodothyronine deiodinases depends
on the hormone infused into the thyroidectomized animals and on the
tissue in which the deiodinase is studied, demonstrating the existence
of tissue-specific regulation of its thyroid hormone concentrations.
(Endocrinology 138: 2559–2568, 1997)
THE METABOLISM of thyroid hormones is mediated byseveral enzymatic reactions, including conjugation,
deamination, oxidative decarboxylation, and deiodination,
which is the predominant mechanism (1). Deiodination of T4
at the 59-position of the phenolic ring can be considered a
bioactivation, as the affinity of the nuclear thyroid hormone
receptor for the resulting T3 is 10- to 20-fold the affinity for
T4 (1–4). On the contrary, deiodination of T4 at the 5-position
of the tyrosyl ring results in an inactivation, as the resulting
rT3 has very low affinity for nuclear thyroid hormone re-
ceptors. Thus, deiodination is a key step in the regulation of
thyroid hormone action, as approximately 80% of the T4
secreted by the thyroid gland is deiodinated (5) either into the
most active thyroid hormone, T3, or into an inactive iodo-
thyronine, rT3. Deiodination is also involved in the main
route of degradation of iodothyronines (i.e. inner ring deio-
dination of T3) and plays a crucial role in the catabolism of
sulfate conjugates of T4 and T3 in the liver (6). Thus, deio-
dination must not be considered an isolated event in thyroid
hormone metabolism, but, rather, a highly regulated step
that is coordinated with other metabolic reactions in several
tissues.
Three major patterns of deiodination have been identified
based on the activity measurements of tissue homogenates
(7), which, according to affinity labeling studies, correspond
to three separate enzymes (8–10), termed types I, II, and III
iodothyronine deiodinases (DI, DII, and DIII). The genes
responsible for these enzymes in several species have re-
cently been cloned (11–15). Although the overall similarity of
these genes is relatively low, there are three highly conserved
limited regions, including a TGA codon that codes for sel-
enocystein, which is essential for catalytic activity (15, 16).
DI can catalyze 59-deiodination of nonsulfated iodothy-
ronine, such as T4 and rT3, or the 5-deiodination of sulfated
conjugates of T4 or T3 (T4S and T3S) (6, 17), and is extremely
sensitive to inhibition by 6-propyl-2-thiouracil (PTU) and
aurothioglucose (2). DI activity is found in liver, kidney,
lung, pituitary gland, and thyroid (18, 19). Its affinity is
higher for rT3, T4S, and T3S than for T4, and its role in liver,
lung, and kidney seems to be the 59-deiodination of rT3 and
the 5-deiodination of iodothyronine sulfates (20), whereas in
the human and rat thyroid it catalyzes the 59-deiodination of
T4 to T3 (2) under the influence of TSH stimulation (21).
DII is present in the central nervous system, brown adi-
pose tissue (BAT), anterior pituitary, and placenta (22–25).
This enzyme is relatively insensitive to PTU, and its affinity
is higher for T4 than for rT3. Brain DII has a primordial role
in ensuring the adequate intracellular concentration of T3 in
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the brain during critical periods of development in fetal and
neonatal rats (26–28). In a recent study, we have also shown
that increased DII activity in hypothyroid adult rats is able
to normalize brain T3 concentrations when T4 is infused at
very low doses that are insufficient to normalize even plasma
T4 and T3 concentrations (29), providing a sensitive mecha-
nism for maintaining brain T3 homeostasis (27, 30). BAT DII
significantly contributes to maintain T3 concentrations in that
tissue (31, 32), explaining the important role of T3 in the full
thermogenic response to cold exposure (33). Finally, pitu-
itary DII contributes significantly to the T3 that reaches the
nuclear receptor, explaining how pituitary function can be
modulated by circulating T4 as well as by circulating T3 (34).
DIII is resistant to PTU and aurothioglucose, and its af-
finity is higher for T3 than for T4 (2), catalyzing their con-
version to 39,3-T2 and rT3, respectively. This enzyme is
present in brain, skin, placenta, and fetal tissues of the rat
(35–37). This distribution suggests that DIII may have pro-
tective properties against high thyroid hormone concentra-
tions during fetal development (2).
The regulation of deiodinase activity involves both pre-
and posttranslational mechanisms and occurs in a tissue- and
enzyme-specific manner (2). Although several factors, such
as cold, fasting, cytokines, GH, retinoids, and drugs, influ-
ence deiodinase activity (16, 38), the main regulator is thyroid
status. Hypothyroidism results in an increased activity of DII
and thyroid DI and a decreased activity of liver and kidney
DI and DIII. Opposite changes are noted in hyperthyroidism
(1). It is well known that T3 stimulates DI messenger RNA
and activity in nearly all tissues studied (11, 39–42), and that
thyroid hormones exert rapid inhibitory effects on DII (30).
Most previous pioneering studies have explored the reg-
ulation of the different iodothyronine deiodinases under
conditions of severe hypo- or hyperthyroidism as well as
their responses to injections of T4 or T3. This methodology
does not permit exploration of the relationships between
enzyme activities and concentrations of iodothyronines in
serum or different tissues, as the time courses of possible
changes in T4 or T3 concentrations and in the activities of the
different deiodinases might differ both within the same tis-
sue and among tissues. In the present study this problem was
obviated by administering T4 or T3 by constant infusion, so
that the different tissues would be in a steady state situation
with regard to both the concentration of iodothyronines and
the activities of the enzymes. As will be seen, the results
provided new insights into the in vivo regulation of iodo-
thyronine deiodinases in various tissues of the rat, and their
consequences for the homeostasis of tissue thyroid hormone
concentrations.
Materials and Methods
Experimental design
Young female Wistar rats, 120–150 g BW, were surgically thyroid-
ectomized and received 100 mCi 131I, ip, 1 week later. After 28 days, rats
with complete body weight stasis were divided into groups of six rats
each, and osmotic minipumps (Alzet, model 2ML2, Alza Corp., Palo
Alto, CA) were implanted under the dorsal skin of the animals. In three
separate experiments, the rats were infused with placebo solution, T4
(Exp A: 1.0, 2.0, 3.0, 4.0, and 8.0 mg/100 g BWzday; Exp B: 0.2, 0.4, 0.6,
0.8, and 1.6 mg/100 g BWzday), or T3 (Exp C: 0.25, 0.50, 0.75, 1.00, and
2.00 mg/100 g BWzday). One group of seven nonthyroidectomized rats,
matched for sex and age and infused with placebo, served as the control
euthyroid group in each experiment.
After 12–13 days of infusion the rats were bled and perfused, as
previously described (29), after being slightly anesthetized with ether.
Samples of plasma, cerebral cortex, pituitary, BAT, liver, lung, and other
tissues were obtained for the present and other studies. Samples were
immediately frozen on dry ice and stored at 220 C until analyzed, with
the exception of aliquots of cortex, pituitary, BAT, liver, and lung that
were stored at 280 C for measurement of iodothyronine deiodinase
activity. The thyroid hormone tissue and plasma concentrations as well
as some preliminary data for deiodinase activities of T4-infused rats were
previously reported (29).
Determinations
T4 and T3 were measured in whole plasma and in tissues after ex-
traction and purification of the iodothyronines by specific and highly
sensitive RIAs, as detailed previously (29, 43).
TSH was measured in plasma using immunoreactants kindly pro-
vided by the Rat Pituitary Agency of the NIDDK, NIH (Bethesda, MD),
as described previously (29, 43). Results are expressed in weight equiv-
alents of the NIDDK rTSH RP-3 preparation.
DII activity was assayed in cortex and BAT (31) using 2 nm T4, 1 mm
T3, and 20 mm dithiothreitol (DTT) in the presence of 1 mm PTU, and
the reaction time was 60 min. DI activity was assayed in liver, pituitary,
and lung homogenates as previously described (26), using 400 nm rT3
and 2 mm DTT for liver, and 2 nm rT3 and 20 mm DTT for pituitary and
lung, in 100 mm potassium phosphate buffer (pH 7.0). The reaction time
was 10 min for liver and 60 min for pituitary and lung. Pituitary DII
activity was evaluated using 2 nm rT3 and 20 mm DTT in the presence
of 1 mm PTU. Before each assay [125I]rT3 or [
125I]T4 was purified by paper
electrophoresis to separate the contaminating iodide. The 125I2 released
was separated by ion exchange chromatography on Dowex 50W-X2
(BioRad, Richmond, CA) columns equilibrated in 10% acetic acid. The
production of equal amounts of iodide and 39,3-diiodothyronine was
checked in some assays. The protein content was determined as previ-
ously described (26, 27, 31) after precipitation of the homogenates with
10% trichloroacetic acid to avoid interference from DTT in the colori-
metric reaction.
DIII activity was measured in cortex homogenates (29), incubating
20–50 mg protein/100 ml in 100 mm potassium phosphate buffer (pH
7.4), 1 mm EDTA with approximately 50,000 cpm of inner ring-labeled
[125I]T3 (3,5-[
125I]T3), 50 nm T3, 20 mm DTT, and 1 mm PTU for 60 min
at 37 C. Radioiodide release was measured as described above. When
necessary, 3,5-[125I]T3 was purified just before the assay using disposable
Sep-Pak C18 cartridges (Waters Associates, Milford, MA).
Drugs and reagents
T4, T3, 3,5-diiodothyronine, PTU, and DTT were obtained from Sigma
Chemical Co. (St. Louis, MO). rT3 and 39,3-diiodothyronine were ob-
tained from Henning Berlin (Berlin, Germany).
High specific activity [131I]T4, [
125I]T3, [
125I]T4, and [
125I]rT3 (3000
mCi/mg) were synthesized in our laboratory and used for highly sen-
sitive T4 and T3 RIAs, as recovery tracers for plasma and tissues ex-
tractions, and as substrates for 59-deiodinases. The inner ring-labeled
3,5-[125I]T3 (80 mCi/mg), used as substrate for DIII, was kindly provided
by Drs. R. Thoma and H. Ro¨kos from Henning Berlin.
Statistical analysis
One-way ANOVA and the protected least significant difference test
for multiple comparisons were used after validation of the homogeneity
of variances by the Bartlett-Box F test. Square root or logarithmic trans-
formations usually ensured homogeneity of variances when this was not
found with the raw data. Results are expressed as the mean 6 sem. P ,
0.05 was considered significant in all comparisons. To compare the
results from the three experiments and to compare the degree of change
observed in the plasma with those in various tissues, iodothyronine
deiodinase activity and T4, T3, and TSH concentrations in samples from
each thyroidectomized rat and from each thyroidectomized rat receiving
different T4 or T3 doses are expressed in the figures as percentages of the
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mean value corresponding to the group of intact controls, which was
taken as 100%.
To assess the relationships between tissue and plasma T3 and T4
concentrations and deiodinase activity, individual paired data, ex-
pressed as percentages of the mean value of the group of intact controls,
as stated above, were adjusted to several curves (linear, logarithmic,
inverse, compound, power, sigmoidal, growth, and exponential). The
curve fit with the highest coefficient of determination (r2), degrees of
freedom, and F statistics was selected for each variable. When T3 alone
was used as replacement therapy for hypothyroidism, the plasma T4
concentration was not included in the curve fitting because its values
were below the limit of detection of our assay in all groups of thyroid-
ectomized rats (plasma T4 resulted in a constant rather than a variable).
Curve fittings with r2 , 0.50, despite statistical significance, are usually
not considered of biological significance, as in such a case less than 50%
of the changes in the dependent variables are explained by related
changes in the independent variable. Statistical analyses were per-
formed with the SPSS for Macintosh versions 4.0 and 6.1.1 (SPSS,
Chicago, IL).
Results
The iodothyronine deiodinase activities, as a function of
the dose of T4 or T3 infused, are described in Table 1 and
represented in Figs. 1-4. The plasma and tissue thyroid
hormone concentrations1 are represented in Figs. 1– 4. The
results of the curve fitting of iodothyronine deiodinase
activities as a function of plasma and tissue thyroid hor-
mone concentrations are represented in Figs. 5–7, and their
curve fitting as a function of plasma TSH is described in
Table 2.
Plasma concentrations of thyroid hormones
In the thyroidectomized rats infused with placebo the
plasma concentrations of T4 and T3 were very low, and the
concentrations of TSH were very high (Fig. 1). In the rats
infused with T4, normal plasma T4 concentrations were
reached in the groups infused with 0.6–1.0 mg/100 g BWzday,
normal plasma T3 concentrations were obtained in the
groups infused with 1.0 and 1.6 mg/100 g BWzday, and both
increased above normal at higher T4 doses (Fig. 1). Plasma
TSH concentrations were normal only in the group infused
1 To permit comparisons between the different experiments, the thy-
roid hormone concentrations are expressed in the figures as percentages
of the mean values of the control group. The absolute values of plasma
and tissue thyroid hormone concentrations and plasma TSH concen-
trations in T4-infused rats were described in detail previously (29). The
absolute values of plasma and tissue thyroid hormone concentrations
and plasma TSH concentrations in T3-infused rats can be derived from
the data points shown in Figs. 1–4, where the 100% values correspond-
ing to the placebo-infused control group of Exp C were: plasma T4, 40 6
2 ng/ml; plasma T3, 0.79 6 0.08 ng/ml; plasma TSH, 0.89 6 0.12 ng/ml;
cerebral cortex T4, 1.73 6 0.25 ng/g; cerebral cortex T3, 2.67 6 0.14 ng/g;
BAT T4, 3.73 6 0.24 ng/g; BAT T3, 3.40 6 0.17 ng/g; pituitary T4, 67 6
9 pg/gland; pituitary T3, 94 6 6 pg/gland; liver T4, 22.74 6 2.77 ng/g;
liver T3, 3.67 6 0.22 ng/g; lung T4, 7.51 6 0.18 ng/g; and lung T3, 1.24 6
0.01 ng/g.
TABLE 1. Mean (6SEM) values of iodothyronine deiodinase activities (DI, DII, and DIII, in femtomoles of I2 per h/mg protein, except for
liver DI, which is in picomoles of I2 per min/mg protein) in control intact rats (C), thyroidectomized rats (Tx) infused with placebo, and Tx
rats infused with T4 or T3
Exp A
Group: C Tx Tx Tx Tx Tx Tx
T4 dose:
a 0 0 1.0 2.0 3.0 4.0 8.0
Cortex DII 9.6 6 0.8 87.8 6 7.7 db 8.3 6 0.5 5 7.6 6 0.4 5 9.3 6 1.8 5 6.3 6 0.4 f 6.1 6 0.3 F
Cortex DIII 2022 6 473 290 6 41 f 861 6 159 5 1405 6 429 5 1619 6 242 5 2499 6 486 5 1270 6 177 5
BAT DII 17 6 2 265 6 34 d 45 6 8 d 17 6 2 5 13 6 1 5 16 6 1 5 24 6 3 d
Liver DI 26 6 2 5 6 1 f 20 6 4 5 41 6 3 d 46 6 5 d 60 6 8 d 94 6 9 d
Lung DI 204 6 16 68 6 3 f 209 6 47 5 218 6 10 5 292 6 12 5 291 6 32 d 422 6 72 d
Exp B
Group: C Tx Tx Tx Tx Tx Tx
T4 dose:
a 0 0 0.2 0.4 0.6 0.8 1.6
Cortex DII 33 6 2 209 6 10 d 123 6 11 d 77 6 19 d 27 6 3 5 35 6 6 5 22 6 1 5
Cortex DIII 1354 6 194 1692 6 603 5 2346 6 768 5 1742 6 679 5 2249 6 677 5 739 6 161 5 3438 6 1452 5
BAT DII 320 6 30 1106 6 76 d 692 6 36 d 381 6 75 5 508 6 86 5 856 6 38 d 147 6 24 5
Pituitary DII 350 6 9 2466 6 117 d 2092 6 205 d 1615 6 250 d 1486 6 175 d 854 6 72 d 408 6 16 5
Pituitary DI 3085 6 72 1216 6 62 f 1505 6 138 f 1972 6 134 f 1721 6 78 f 1904 6 121 f 2486 6 95 F
Liver DI 52 6 4 16 6 2 f 22 6 2 f 18 6 2 f 28 6 2 f 31 6 2 f 52 6 4 5
Lung DI 557 6 17 144 6 9 f 166 6 16 f 183 6 9 f 245 6 39 f 283 6 31 f 359 6 19 5
Exp C
Group: C Tx Tx Tx Tx Tx Tx
T3 dose:
a 0 0 0.25 0.50 0.75 1.00 2.00
Cortex DII 75 6 8 403 6 11 d 537 6 10 d 575 6 29 d 617 6 30 d 454 6 4 d 360 6 31 d
Cortex DIII 1487 6 94 1111 6 367 5 1299 6 291 5 1754 6 167 5 1883 6 185 5 2588 6 488 d 3241 6 522 d
BAT DII 508 6 86 1429 6 105 d 1035 6 44 d 1184 6 35 d 901 6 55 d 1303 6 85 d 817 6 79 d
Pituitary DII 657 6 12 2953 6 140 d 2243 6 227 d 1327 6 38 d 987 6 80 d 939 6 67 d 1040 6 43 d
Pituitary DI 3940 6 109 1822 6 235 f 3107 6 368 5 4438 6 237 5 6082 6 402 d 7836 6 315 d 7587 6 628 d
Liver DI 16 6 1 12 6 1 f 19 6 1 D 32 6 1 d 45 6 2 d 52 6 2 d 126 6 8 d
Lung DI 551 6 37 184 6 13 f 515 6 40 5 774 6 19 d 1081 6 87 d 923 6 96 d 1314 6 59 d
Cortex, cerebral cortex; BAT, brown adipose tissue.
a The doses are in micrograms per 100 g BW/day.
b The symbols represent the comparison of the mean values from T4- or T3-infused rats with those from control rats infused with placebo:
5 indicates that there were no statistically significant differences; and f identifies low levels compared to controls, with at least P , 0.05; d
identifies elevated levels compared to controls, with at least P , 0.05. An open arrow (D or F) indicates that, although statistically significant,
the change with respect to controls was relatively small, within 630% of the mean of the control group.
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with 1.6 mg/100 g BWzday; plasma TSH levels were elevated
in the groups infused with lower T4 doses and decreased in
the groups infused with higher T4 doses (Fig. 1).
Plasma T4 concentrations were below the limit of detection
of the assay in all groups of thyroidectomized rats infused
with T3 (Fig. 1). Plasma T3 was already normal in the group
infused with 0.25 mg/100 g BWzday and elevated in the
groups infused with higher T3 doses (Fig. 1). Finally, the
plasma TSH concentration was elevated in the group infused
with 0.25 mg/100 g BWzday and low in the groups infused
with higher T3 doses (Fig. 1).
Cerebral cortex DII
Cerebral cortex DII activity was markedly elevated in thy-
roidectomized rats infused with placebo (Table 1 and Fig. 2).
When T4 was infused into thyroidectomized rats, cortex DII
activity showed a progressive decrease, reaching normal ac-
tivities with T4 doses between 0.6–3.0 mg/100 g BWzday,
whereas the groups infused with the higher T4 doses (4.0 and
8.0 mg/100 g BWzday) showed decreased DII activity with
respect to controls (Table 1 and Fig. 2). Cerebral cortex T3
concentrations reached normal levels with T4 doses from
0.4–8.0 mg/100 g BWzday, with the exception of a slight
increase in the group infused with 1.6 mg/100 g BWzday (Fig.
2). On the contrary, cortex T4 concentrations were low in the
groups infused with 0.2–0.8 mg/100 g BWzday and high in
the groups infused with 1.0–8.0 mg/100 g BWzday (Fig. 2).
In contrast to the result of infusion of T4 alone, when T3
was infused into thyroidectomized rats, cortex DII activity
remained elevated, as none of the doses of T3 infused was
able to normalize its activity. Moreover, DII activity was
further increased, compared to the activities found in ani-
mals infused with placebo, with T3 doses of 0.25, 0.50, and
0.75 mg/100 g BWzday (Table 1 and Fig. 2). Cerebral cortex
T3 concentrations reached normal levels in the group infused
with 0.75 and 1.00 mg/100 g BWzday and were elevated with
the higher T3 dose (Fig. 2). As expected, cerebral cortex T4
concentrations were low in all groups infused with T3 (Fig.
2).
DII activity in the cerebral cortex of rats infused with T4
was related to both plasma and cortex T4 and T3 (Fig. 5). In
the rats infused with T3, DII activity was only related to
cortex T4 and plasma T3, but the curve fittings were not
strong enough (r2 , 0.50) to ensure biological significance
(Fig. 5).
Cerebral cortex DIII
DIII activity in cerebral cortex showed inconsistent results
in the groups infused with placebo, as this activity was re-
duced with respect to that in the control group only in Exp
A, but remained normal in Exp B and C (Table 1). In the
groups infused with T4, cerebral cortex DIII activity was not
different from the control value, and the small changes
present between the groups infused with different T4 doses
were not related to the changes in cortex T4 or T3 levels (Table
1).
On the contrary, in the animals infused with T3 alone, DIII
activity increased with the higher T3 doses and higher cortex
T3 concentrations (Table 1 and Fig. 2). In this experiment, the
changes in DIII activity were weakly related to the changes
in cortex and plasma T3 (compound curve fitting: r
2 5 0.43;
P , 0.01; power curve fitting: r2 5 0.37; P , 0.01).
BAT DII
BAT DII activity was markedly elevated in thyroidecto-
mized rats infused with placebo (Table 1 and Fig. 2). When
T4 was infused, DII activity showed an irregular pattern of
response, showing a tendency to normalization with the
higher T4 doses (Table 1 and Fig. 2). BAT showed an accept-
able homeostasis in its T3 concentrations, which were normal
FIG. 1. The changes in plasma T4 and T3 concentrations (upper pan-
els, full and empty circles, respectively) and in plasma TSH (lower
panels, full squares) of thyroidectomized rats infused with placebo, T4
alone (left panels), or T3 alone (right panels) are represented as a
function of the dose of T4 or T3. Values shown are the mean 6 SEM and
are expressed as percentages of the mean value in control intact
animals (see Footnote 1). The absence of vertical lines for the SEMs is
due to their being within the dimension of the symbol. The areas
enclosed by horizontal lines represent the 95% confidence intervals of
the plasma T4 (full lines, dotted area) and T3 (dotted lines, white area)
concentrations of intact control rats. The horizontal line in the lower
panels resulted from the area representing the 95% confidence in-
terval of plasma TSH concentrations of the control group, which
appears as a line because of the reduction in the size of the figure. The
two left panels showing the plasma T4, T3, and TSH concentrations in
T4-infused animals are taken from the report by Escobar-Morreale et
al. (29) and are reproduced from The Journal of Clinical Investigation
96:2828–2838, 1995, by copyright permission of the American Society
for Clinical Investigation and with permission of the authors.
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in all groups infused with T4, with the exception of low levels
in the groups infused with 0.2, 0.4, and 1.6 mg/100 g BWzday
(Fig. 2). As occurred with BAT DII activity, the changes in
BAT T4 concentrations were highly irregular. These T4 values
might be questioned because of the proximity of the inter-
scapular BAT pads to the site where the osmotic pump is
implanted and from which it is only separated by an easily
punctured, thin layer of connective tissue. Although care was
taken at autopsy to avoid contact between the BAT pads and
fluid surrounding the T4-containing pumps, some external
contamination with T4 might have occurred; for this reason
the data have not been shown.
BAT DII activity decreased when T3 was infused into thy-
roidectomized rats, but its activity did not reach normal
values at any of the T3 doses tested (Table 1 and Fig. 2),
although BAT T3 concentrations were normal in the groups
infused with 0.75 mg/100 g BWzday or more (Fig. 2). As
expected, T4 concentrations were very low in all groups of
thyroidectomized rats infused with T3 (Fig. 2).
BAT DII activity in thyroidectomized rats receiving T4
alone showed sigmoidal relationships to plasma T3 and T4
(Fig. 5). Curve fitting of BAT DII activity against tissue and
plasma T4 and T3 concentrations disclosed only weak rela-
tionships in rats infused with T3 (Fig. 5).
Pituitary DII and DI
Pituitary DII activity was markedly elevated, and DI ac-
tivity was markedly decreased, in thyroidectomized rats in-
fused with placebo (Table 1 and Fig. 3).
The effects of T4 infusion on pituitary 59-deiodinase ac-
tivities were evaluated only in Exp B, as, unfortunately, no
aliquots of pituitary homogenate were saved before extrac-
tion in Exp A. Pituitary DII activity showed a progressive
decrease with the increasing T4 doses infused, reaching nor-
mal values with the dose of 1.6 mg/100 g BWzday (Table
1 and Fig. 3). Pituitary DI activity showed the opposite
change, increasing with the increasing T4 doses, but re-
mained slightly decreased (81% of the mean value of the
control group) with respect to the control value with the
higher dose of 1.6 mg/100 g BWzday (Table 1 and Fig. 3).
Pituitary T4 concentrations were low in the group infused
with 0.2 mg/100 g BWzday; normal in the groups infused
with 0.4, 0.6, 1.0, and 2.0 mg/100 g BWzday; and elevated
in the groups infused with 0.8, 1.6, and 3.0 – 8.0 mg/100 g
BWzday (Fig. 3). Pituitary T3 concentrations reached nor-
mal levels in the groups infused with T4 doses ranging
from 1.0 –3.0 mg/100 g BWzday and were elevated in those
given higher T4 doses (Fig. 3).
When the animals were infused with T3, the changes in
pituitary DII activity resembled those in BAT. Although
there was a progressive decrease in DII activity, it remained
elevated in the group infused with the higher T3 dose (Table
1 and Fig. 3). On the contrary, pituitary DI activity reached
normal levels in the groups infused with 0.25 and 0.50 mg/
100 g BWzday and was elevated with higher T3 doses (Table
1 and Fig. 3). Pituitary T3 reached normal concentrations in
the groups infused with 0.50 and 0.75 mg/100 g BWzday and
was elevated with higher T3 doses (Fig. 3). As expected,
pituitary T4 concentrations were low in all groups infused
with T3 (Fig. 3).
Finally, both pituitary DI and DII activities in thyroidec-
tomized rats given T4 alone were related to pituitary and
plasma T4 and T3 (Fig. 6), and the best fit was obtained for
both deiodinases with pituitary T4. On the contrary, when the
animals were infused with T3 alone, pituitary DI and DII
activities were only related to plasma and pituitary T3
(Fig. 6).
FIG. 2. The changes in DII (full dia-
monds) and DIII (open triangles) activ-
ities and in tissue concentrations of T4
(full circles) and T3 (empty circles) in
cerebral cortex and BAT of thyroidec-
tomized rats infused with placebo, T4
alone, or T3 alone are shown as function
of the dose of T4 (left panels) or T3 (right
panels). As nonsystematic changes
were found in the cerebral cortex DIII
activity of rats infused with T4 alone,
their plots have been removed from the
figure. The tissue T4 concentrations of
BAT in the animals infused with T4
have been removed from the figure for
the reasons outlined in the text. The
expression of data and the meaning of
dotted and white areas are explained in
Fig. 1. The panels showing the T4 and T3
concentrations in the cerebral cortex
and BAT of T4-infused animals are
taken from the report by Escobar-
Morreale et al. (29) and are reproduced
from The Journal of Clinical Investiga-
tion 96:2828–2838, 1995, by copyright
permission of the American Society for
Clinical Investigation and with permis-
sion of the authors.
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Liver DI
Liver DI activity was markedly decreased in thyroidecto-
mized rats infused with placebo (Table 1 and Fig. 4). In the
rats infused with T4, liver DI activity reached normal levels
with 1.0 and 1.6 mg/100 g BWzday and was elevated with
higher T4 doses (Table 1 and Fig. 4). The changes in liver DI
activity paralleled closely those in plasma T3, whereas the
concordance with liver T3 and T4 was not complete (Table 1
and Fig. 4). Liver DI activity in rats infused with T4 was
related to plasma T4 and T3 and to liver T3 and T4 (Fig. 7).
Liver DI activity was increased in all groups infused with
T3, showing some concordance with liver T3 (Table 1 and Fig.
4). Liver DI activity was related to plasma and liver T3 and,
surprisingly, to liver T4 (Fig. 7), although the latter concen-
trations were extremely low (Fig. 4).
Lung DI
Lung DI activity was markedly decreased in thyroidecto-
mized rats infused with placebo (Table 1 and Fig. 4). In the
rats infused with T4, lung DI activity reached a normal value
with 1.0–3.0 mg/100 g BWzday (the dispersion in the lung DI
activity of the control group was high) and was elevated with
higher T4 doses (Table 1 and Fig. 4). The changes in lung DI
activity paralleled those in lung T3 (Fig. 4) and were mainly
related to plasma and lung T3 and, to a lesser degree, plasma
and lung T4 (Fig. 7).
When T3 was infused into thyroidectomized rats, lung DI
activity was normal with the dose of 0.25 mg/100 g BWzday
and elevated with higher T3 doses (Table 1 and Fig. 4). Similar
changes were observed in lung T3 concentrations, whereas
lung T4 levels were very low (Fig. 4). Lung DI activity was
related to plasma and lung T3 (Fig. 7).
Relationships between plasma TSH concentration and
iodothyronine deiodinase activities
Cerebral cortex and BAT DII activity showed weak or
nonsignificant relationships with plasma TSH concentra-
tions regardless of whether T4 or T3 was infused into thy-
roidectomized rats (Table 2). On the contrary, the changes in
pituitary DII activity and in pituitary, liver, and lung DI
activities were related to the changes in plasma TSH con-
centrations (Table 2). Pituitary DII activity was directly re-
lated to TSH, as expected from the fact that both increase in
response to hypothyroidism, whereas DI activity in pituitary,
liver, and lung, was inversely related to the change in plasma
TSH, reflecting the expected opposite response to the change
in thyroid function (Table 2). Finally, the change in cerebral
cortex DIII in the animals infused with T3 alone showed a
weak, but significant, relationship with plasma TSH (Table
2).
Discussion
Thyroidal status is the main regulator of iodothyronine
deiodinase activity. DII activity increases in response to hy-
pothyroidism (30) and decreases in response to hyperthy-
roidism. On the contrary, DI activity decreases in hypothy-
roid situations and increases in hyperthyroidism, with the
exception of the thyroidal enzyme, which is under the control
of plasma TSH (21). Our results show that the degree of
response of each enzyme to thyroidal status is different de-
pending on the tissue studied and the hormone infused.
Type II 59-deiodinase and type III 5-deiodinase
As expected, DII activity is increased in cerebral cortex,
BAT, and pituitary in thyroidectomized animals infused
with placebo. In the three tissues studied, DII activity de-
creases in response to T4 infusion, reaching normal levels
after tissue T3 euthyroidism is reached. However, when T3 is
infused, DII activity does not normalize even in the presence
of normal or high tissue T3 concentrations. In contrast to BAT
and pituitary DII, which tended to decrease with the increase
in T3 concentrations, cerebral cortex DII activity actually
increases in this situation. Recent results from our group
have shown a similar T3-induced increase in DII activity in
fetal BAT (44). Present results point to T4, but not T3, as the
main down-regulator of cerebral cortex and BAT DII activity
(27, 29). Moreover, the tight tissue homeostasis of the T3
concentration in the cerebral cortex and BAT is only main-
tained when T4 is supplied to the thyroidectomized animals,
FIG. 3. The changes in DII (full diamonds) and DI (open diamonds)
activities and in tissue concentrations of T4 (full circles) and T3 (empty
circles) in the pituitary of thyroidectomized rats infused with placebo,
T4 alone, or T3 alone are shown as function of the dose of T4 (left
panels) or T3 (right panels). The expression of data and the meaning
of dotted and white areas are explained in Fig. 1.
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further suggesting that DII activity and T4 are intimately
related, with the former using the latter as substrate to pro-
vide T3, especially in hypothyroid situations. Finally, al-
though a stimulatory effect of TSH on DII expression has
been described in astrocytes (45), our data have failed to
confirm this hypothesis, as the changes in cortex DII activity
in rats infused with T3 did not shown any relationship with
changes in plasma TSH.
Pituitary DII activity showed a different pattern of re-
sponse to T4 infusion compared to DII in the cortex and BAT.
Pituitary DII needed elevated pituitary T4 concentrations and
normal pituitary T3 concentrations to normalize its activity.
This result might be related to the presence of DI activity in
pituitary, as the T3 produced from T4 by pituitary DI might
be exported into the circulation instead of contributing to
local T3 concentrations. In fact, a similar physiological role
has been suggested for DI activity in other tissues, such as
liver and kidney (2). In contrast to the cerebral cortex and
BAT enzymes, pituitary DII activity showed a strong rela-
tionship with pituitary and plasma T3 during T3 infusion, a
result that suggests that at least to some extent in the pitu-
itary, DII activity is sensitive to the inhibitory effects of T3.
This conclusion is also supported by others using single
iodothyronine injections in vivo (46). Unfortunately, we were
not able to measure pituitary iodothyronine deiodinase ac-
tivities in Exp A, and thus, we do not have data regarding the
pattern of response of these activities in T4-induced
hyperthyroidism.
When hyperthyroidism was induced by infusion of very
high doses of T4 or T3, cerebral cortex DII activity only
showed a mild decrease with T4 infusion and remained
elevated when T3 alone was infused. BAT DII activity did
not decrease with respect to the control value and, in fact,
was slightly elevated with the highest T4 dose infused. In
this situation, cerebral cortex and BAT T3 concentrations
were normal or only mildly elevated (cerebral cortex T3 in
FIG. 4. The changes in DI activity
(open diamonds) and tissue concentra-
tions of T4 (full circles) and T3 (empty
circles) in liver and lung of thyroidecto-
mized rats infused with placebo, T4
alone, or T3 alone are shown as function
of the dose of T4 (left panels) or T3 (right
panels). The expression of data and the
meaning of dotted and white areas are
explained in Fig. 1. The panels showing
the T4 and T3 concentrations in the liver
and lung of T4-infused animals are
taken from the report by Escobar-Mor-
reale et al. (29) and are reproduced from
The Journal of Clinical Investigation
96:2828–2838, 1995, by copyright per-
mission of the American Society for
Clinical Investigation, and with per-
mission of the authors.
TABLE 2. Results of the curve fitting between iodothyroine deiodinase activity and plasma TSH in thyroidectomized rats infused with T4
or T3 alone
Deiodinasea
Plasma TSH-T4 infusion Plasma TSH-T3 infusion
Fitb r2 Fit r2
Cerebral cortex DII Power 0.38 No significant fitting was found
Cerebral cortex DIII No significant fitting was found Compound 0.32
BAT DII Power 0.30 Linear 0.20
Pituitary DII Power 0.72 Linear 0.93
Pituitary DI Logarithmic 0.54 Power 0.80
Liver DI Power 0.70 Sigmoid 0.78
Lung DI Power 0.75 Inverse 0.78
Before curve fitting, raw data were transformed into percentages of the mean value of the control group. The 95% confidence interval for
the normal plasma TSH concentrations were 77–123% of the mean control values (TSH, 1.02 ng/ml).
a DI, Type I 59-deiodinase; DII, type II 59-deiodinase; DIII, type III 5-deiodinase; BAT, brown adipose tissue.
b The curve with the best fitting (defined by the highest r2 and F values) was selected. Unless otherwise stated, all fittings were significant
(P , 0.05).
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animals infused with T3), pointing to mechanisms other
than inhibition of DII as those responsible for the protec-
tion of brain and BAT against hyperthyroidism. DIII is
present in the central nervous system and catalyzes the
inactivation of T4 into rT3 and that of T3 into T2. Although
some researchers have found a decrease in brain DIII ac-
tivity in hypothyroidism and an increase in hyperthyroid-
ism, with the latter having protective properties against
elevated thyroid hormone concentrations (47), we have
not been able to confirm these results. Cerebral cortex DIII
showed low activities in thyroidectomized rats infused
with placebo only in Exp A, not in Exp B and C. Con-
versely, elevated DIII activity was only found in the
groups infused with the higher T3 doses in Exp C, but not
in animals in which hyperthyroidism was induced by the
infusion of T4. The latter result might be related to a high
efficiency of DIII in the degradation of T4 and T3, thus
maintaining normal or near-normal tissue T3 concentra-
tions with minor increases in DIII activity. On the other
hand, if T3 homeostasis is achieved through other regu-
latory mechanisms, the changes in tissue T3 might not be
enough to induce changes in DIII activity. Other mecha-
nisms not implicating iodothyronine deiodinases, such as
reduction in the transthyretin-mediated T4 transport at the
choroid plexus (48) or a decreased T3 permeability of the
blood-brain barrier, might be involved in protection of the
cerebral cortex against hyperthyroidism, but do not ex-
plain the homeostasis of BAT T3 or pituitary T3.
DI
As expected, DI activity was decreased during hypothy-
roidism and increased during hyperthyroidism in pituitary,
liver, and lung. However, the magnitude of the changes in
response to thyroidal status was not the same in all of these
tissues, pointing to tissue-specific factors regulating deiodi-
FIG. 5. Best-fit curves obtained for DII
in cerebral cortex and BAT of thyroid-
ectomized rats infused with T4 alone
(full symbols) or T3 alone (open symbols)
as a function of tissue and plasma T4 or
T3 concentrations. The values are ex-
pressed as a percentage of the mean
value in the control group. The dotted
square inset separates the values below
and above those in control intact rats.
The thin diagonal line corresponds to
the relationship that would be found if
the changes in deiodinase activity were
accompanied by changes of equal inten-
sity in T4 or T3 concentrations. R
2 is the
coefficient of determination. Values be-
low 0.5 seldom have biological signifi-
cance.
FIG. 6. Best-fit curves obtained for DI
(circles) and DII (diamonds) activities
in the pituitary of thyroidectomized
rats infused with T4 alone (full symbols)
or T3 alone (open symbols) as a function
of tissue and plasma T4 or T3 concen-
trations. The values are expressed as a
percentage of the mean value in the con-
trol group. The meaning of dotted areas
and lines is the same as indicated in Fig.
5. R2 is the coefficient of determination.
Values below 0.5 seldom have biological
significance.
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nase activity. Moreover, the relationships of iodothyronine
deiodinase activity with plasma and tissue thyroid hormones
were different depending on which iodothyronine, T4 or T3,
was infused.
Pituitary DI activity increases nearly in parallel with pi-
tuitary T3 when either T4 or T3 is infused. This finding sug-
gests a regulatory role of pituitary T3 on pituitary DI activity,
in agreement with studies performed in pituitary cells in vitro
(49). With infusion of increasing doses of T3, plasma T3
reached an approximately 5-fold increase with respect to the
control value, whereas pituitary T3 and DI activity only
showed 2-fold increases. On the contrary, when T4 alone was
infused, changes in plasma T3, pituitary T3, and pituitary DI
activity were similar. This result is in agreement with pre-
vious studies in which most of pituitary T3 is derived from
local conversion of T4 to T3 (23, 50). When T4 is absent, the
only source of pituitary T3 is the circulating T3, and supra-
physiological plasma T3 concentrations must be reached to
normalize pituitary T3.
Liver DI activity changed in parallel with plasma and tissue
T3 regardless of whether T4 or T3 was used as replacement
therapy. The highest increases in liver DI activities were reached
with the highest T4 or T3 dose and were approximately 1.5-fold
the simultaneous increases in plasma and liver T3. On the con-
trary, lung DI activity was differentially affected by changes in
thyroid hormone concentrations depending on whether T4 or
T3 was infused. During T4 infusion, lung DI activity changed in
parallel with plasma T4 and T3 and tissue T3. On the contrary,
when T3 was infused, the increase in lung DI activity was
approximately a third of the increase in plasma and lung T3.
This might result from a stimulatory effect of T4 or the lung T3
generated by local conversion from T4 on lung DI activity and
a lack of effect of lung T3 derived directly from plasma. Other
possibilities include an enhanced sulfation of thyroid hormones
in lung during T4 infusion, which, in turn, might stimulate lung
DI activity, or a saturation of the stimulatory effect of T3 on DI
activity when very high levels of lung T3 are reached during T3
infusion.
Summary
The results of the present study demonstrate that the in vivo
regulation of iodothyronine deiodinases in the rat is different
depending on the tissue studied. Especially important is the fact
that our experimental design has permitted us to study the
mechanisms that regulate tissue iodothyronine concentrations
under steady state conditions resulting in variable degrees of
hypo- or hyperthyroidism. This experimental approach might
mimic the physiological and pathological abnormalities of thy-
roid function better than previous studies performed with sin-
gle or intermittent injections of T4 or T3.
The present results further support the existence of tissue-
specific mechanisms that regulate thyroid hormone concentra-
tions in target tissues (29). None of the single doses of T4 or T3
tested has been able to normalize each iodothyronine deiodi-
nase simultaneously in the tissues in which it was present or
even to simultaneously normalize DI and DII in tissues with
both activities (i.e. the pituitary). Thus, the pattern of regulation
by thyroid hormones of the iodothyronine deiodinases depends
on the tissue studied, the iodothyronine infused, its dose, and,
possibly, the route of administration, explaining the frequent
discrepancies found in the literature regarding this issue. The
same occurs with the T4 and T3 concentrations in plasma and
tissues (29). On the contrary, tissue concentrations of T4 and T3
and iodothyronine deiodinase activities in the tissues studied
here reach normal values simultaneously when a combination
of 0.9 mg T4 and 0.15 mg T3/100 g BWzday is infused, as pre-
viously reported (43).
According to our present results, tissues with DII ac-
tivity show a high degree of homeostasis of their T3 con-
centrations. The increase in DII activity explains the effi-
ciency of cerebral cortex, BAT, and pituitary in the
normalization of tissue T3 in situations of hypothyroidism,
but does not explain the protection against elevated cir-
culating thyroid hormone levels shown by these tissues.
The possible role of cortex DIII in this protection has been
only partially supported by our data. Finally, as opposed
FIG. 7. Best-fit curves obtained for DI
activity in liver and lung of thyroidec-
tomized rats infused with T4 alone (full
symbols) or T3 alone (open symbols) as a
function of tissue and plasma T4 or T3
concentrations. The values are ex-
pressed as a percentage of the mean
value in the control group. The meaning
of dotted areas and lines is indicated in
Fig. 5. R2 is the coefficient of determi-
nation. Values below 0.5 seldom have
biological significance.
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to tissues with DII activity, tissues in which DI activity is
preferentially expressed maintain thyroid hormone con-
centrations similar to those in plasma. This finding might
be explained by two nonexclusive hypotheses for such
tissues: their thyroid hormone concentrations are in equi-
librium with circulating levels and/or the T3 generated in
these tissues is the main source of circulating T3.
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